Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum

Area of Science:

• Parasitology
• Drug Discovery
• Biochemistry

Background:

• Cryptosporidium parvum causes significant diarrheal disease and mortality, particularly in children and immunocompromised individuals.
• Current treatments for cryptosporidiosis are ineffective in vulnerable populations, highlighting an urgent need for new therapeutic strategies.
• The parasite poses a threat to both human and animal health, emphasizing the broad impact of cryptosporidiosis.

Purpose of the Study:

• To identify novel anti-cryptosporidial compounds through drug repurposing of existing human kinase inhibitors.
• To evaluate the efficacy of kinase inhibitors against Cryptosporidium parvum using phenotypic screening.
• To discover potential drug candidates for treating cryptosporidiosis, addressing a critical unmet medical need.

Main Methods:

• A library of 473 human kinase inhibitors was screened for activity against Cryptosporidium parvum.
• Phenotypic screening utilized a transgenic C. parvum strain expressing a luciferase reporter for compound evaluation.
• Dose-response assays and kinome profiling were performed on identified hit compounds to determine potency and target selectivity.

Main Results:

• Sixty-seven novel anti-cryptosporidial compounds were identified from the kinase inhibitor library.
• Eleven hit compounds demonstrated potent inhibition of C. parvum at nanomolar concentrations.
• Kinome profiling revealed that several prioritized hits selectively target specific kinase families, notably tyrosine kinases.

Conclusions:

• Tyrosine kinase inhibitors show significant potential as new drug candidates for treating cryptosporidiosis.
• The study identified novel compounds and potential kinase targets for future anti-parasitic drug development.
• Drug repurposing of kinase inhibitors offers a promising avenue for addressing the global burden of cryptosporidiosis.